Type 2 diabetes
Conditions
Interventions
None listed
Sponsors
Yokohama City University hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Outpatients and inpatients with type 2 diabetes who fulfilled the following criteria. <GLP-1 receptor agonists group> 1) Age is over 20. 2) Patients diagnosed with type 2 diabetes. 3) Patients scheduled to start the treatment with GLP-1 receptor agonist. 4) Having provided voluntary written consent for participation in this study. <Control group (insulin group)> 1) Age is over 20. 2) Patients diagnosed with type 2 diabetes. 3) Patients scheduled to start the treatment with insulin injection. 4) Having provided voluntary written consent for participation in this study.
Exclusion criteria
Exclusion criteria: Patients corresponding to any of the following are inapplicable in the both GLP-1 receptor agonists group and control group. 1)Patients who ingest the DPP-4 inhibitors. 2)Patients with severe complications (liver disease, mental disorder, or cancer). 3)Patients with severe ketosis or diabetic coma. 4)Patients with severe infections, perioperative status, or severe trauma. 5)Patients whose baseline eGFR were <29 ml/min/1.73m^2. 6)Pregnancy or lactation in women. 7)Patients who are judged by an investigator to be inappropriate for this study for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes in serum Serpina3 / EGFR levels in type 2 diabetes patients before and after administering the GLP-1 receptor agonists. | — |
Secondary
| Measure | Time frame |
|---|---|
| The association of metabolic parameters with the difference in serum Serpina3 / EGFR levels in type 2 diabetes patients between before and after administering GLP-1 receptor agonist. | — |
Countries
Japan
Contacts
Public ContactMayu Kyohara
Yokohama City University Graduate School of Medicine Department of Endocrinology and Metabolism
Outcome results
None listed